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Metallo--lactamases (MLs) are zinc-dependent enzymes
able to hydrolyze and inactivate most -lactam antibiotics. The
large diversity of active site structures andmetal content among
MLs from different sources has limited the design of a pan-
ML inhibitor. Here we report the biochemical and biophysical
characterization of a novelML,GOB-18, from a clinical isolate
of a Gram-negative opportunistic pathogen, Elizabethkingia
meningoseptica. Different spectroscopic techniques, three-di-
mensional modeling, and mutagenesis experiments, reveal that
the Zn(II) ion is bound to Asp120, His121, His263, and a solvent
molecule, i.e. in the canonical Zn2 site of dinuclear MLs. Con-
trasting all other related MLs, GOB-18 is fully active against a
broad range of -lactam substrates using a single Zn(II) ion in
this site. These data further enlarge the structural diversity of
MLs.
The expression of -lactam degrading enzymes (-lactama-
ses) is the most common mechanism of antibiotic resistance
among bacteria (1, 2). These enzymes have been grouped into
four classes (A–D) according to sequence homology (3, 4).
Class A, C, and D enzymes use an active site serine residue as a
nucleophile, whereas class B lactamases (generically termed
metallo--lactamases,MLs)9 employ one or twoZn(II) ions to
cleave the -lactam ring.
MLs have particular importance in the clinical setting since
they can hydrolyze a broader spectrum of -lactam substrates
than the serine-type enzymes and are resistant to most clini-
cally employed inhibitors (5–11). The design of an efficient
pan-ML inhibitor has been mostly limited by a striking diver-
sity in the active site structures, catalytic features, andmetal ion
requirements for activity among different enzymes. Based on
this heterogeneity, MLs have been classified into three sub-
classes: B1, B2, and B3 (3, 6). Subclass B1 includes several chro-
mosomally encoded enzymes such as BcII from Bacillus cereus
(12–14), CcrA from Bacteroides fragilis (15–18), BlaB from
Elizabethkingia meningoseptica (formerly, Chryseobacterium
meningosepticum) (19), as well as the transferable VIM (20)-,
IMP (21, 22)-, SPM (23, 24)-, and GIM-type enzymes. Subclass
B2 includes the CphA (25, 26) and ImiS (27) lactamases from
Aeromonas species. Subclass B3, originally represented only by
L1 from Stenotrophomonas maltophilia (28–30), now includes
enzymes from other opportunistic pathogens like FEZ-1 from
Legionella gormanii (31) andGOB from E.meningoseptica (32),
as well as from environmental bacteria such as CAU-1 from
Caulobacter crescentus (33) and THIN-B from Janthinobacte-
rium lividum (34).
Molecular structures ofMLs from the three subclasses have
been solved by x-ray crystallography (12, 14, 15, 25, 31). Com-
parison of the tertiary structure of enzymes belonging to the
different subclasses reveals a common / sandwich fold, in
which different insertions and deletions have resulted in differ-
ent loop topologies and, ultimately, in different zinc coordina-
tion environments and metal site occupancies among B1, B2,
and B3 enzymes (Fig. 1). MLs bind up to two metal ions in
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their active sites. In B1 and B3 enzymes, one Zn(II) ion (Zn1)
is tetrahedrally coordinated to three histidine ligands
(His116, His118, and His196 in Fig. 1) and a water/OH mol-
ecule (3-H site) (14, 15, 28). The coordination polyhedron of
Zn2 in B1 enzymes is provided by Asp120, Cys221, His263, and
one or two-water molecules (DCH site). Notably, this site
represents the active species in mono-Zn(II) B2 enzymes
(25). Instead, two mutations (Cys221 3 Ser and Arg121 3
His) affect the Zn2 coordination geometry in B3 MLs, and
the metal ion is bound to Asp120, His121, His263, and one- or
two-water molecules, while Ser221 is no longer a metal ligand
(DHH site) (28). A remarkable exception is provided by the
deepest branching member of the ML B3 subclass, GOB
from E. meningoseptica (4). In all reported GOB sequences,
His116 and Ser221 are substituted by Gln and Met, respec-
tively, suggesting the presence of an unusually perturbed
metal binding site.
Here we show that E. meningoseptica GOB-18 represents a
novel type of broad spectrum ML unique in being maximally
active in the mono-Zn(II) form and in which the metal ion
occupies only the Zn2, DHH site. This contrasts with two gen-
erally accepted ideas: broad spectrum MLs are maximally
active in the dinuclear form (B1 and B3 enzymes), and mono-
Zn(II) enzymes are carbapenemases (B2 enzymes). Finally, the
findings presented here confirm that Zn2 is central for ML-
mediated catalysis and that the attacking nucleophile could be
provided either by a non-metal center or by the Zn2 site. This
claims for a revisited strategy for the design of broad spectrum
ML inhibitors.
EXPERIMENTAL PROCEDURES
Source of GOB-18 Coding Sequence—An E. meningoseptica
clinical strain from the Hospital Clemente Alvarez (Rosario,
Argentina), identified by API 20NE (bioMerieux, Marcy
l’Etoile, France), was used as the source of the genomicDNA for
cloning the GOB-18 coding gene.
DNA Cloning and Construction of the Expression Vector for
GOB-18—Genomic DNA from the E. meningoseptica clini-
cal strain used here was isolated essentially as described in
ref (35). The complete coding sequence of the gob-18 gene
was amplified by employing primers 1 and 2 described in Ref.
32. The DNA fragment was sequenced and two new primers
were designed (see supplemental material) to clone the
mature GOB-18 coding sequence cloned into BamHI-Hin-
dIII sitesofpETGEXTermvector (13)
in frame to the 3-end of Schistosoma
japonicus glutathione S-transferase
gene, for expression purposes. The
resulting recombinant pET-GOB-18
plasmidproducesGOB-18 as aC-ter-
minal fusion to glutathione S-trans-
ferase. The nucleotide sequence
reported in this paper was assigned
accession number DQ004496 in the
combined EMBL/GenBankTM/DDBJ
sequence data base.
Site-directed Mutagenesis—Site-
directed mutagenesis was achieved
using a rapid PCR-based method with modifications (36 and
see supplemental material).
Protein Expression and Purification—GOB-18 wild-type and
mutants were overproduced in Escherichia coli BL21(DE3)
pLysS and E. coli BL21(DE3) Codon Plus RIL cells, respectively,
transformed with plasmid pET-GOB-18, pET9a-Gln1163His
GOB-18, pET9a-Asp1203 Ser GOB-18, or pET9a-
Cys2013 Ser GOB-18. We followed protein expression and
purification procedures described before (13) with modifica-
tions. The purification average yields were of 12 mg of
GOB-18 or Cys2013 Ser GOB-18, 6mg of Gln1163His GOB-
18, and 3 mg of Asp1203 Ser GOB-18, per liter of culture, and
rendered polypeptides of 31 kDa at a purity higher than 95%, as
estimated by SDS-PAGE (37). Pure enzymes were dialyzed
twice against 100 volumes of 15 mMHepes, pH 7.5, NaCl 0.2 M,
pooled, and then stored at 4 °C for immediate use. The concen-
tration of purified enzymes was determined by measuring the
absorbance at 280 nm in a Jasco V-550 spectrophotometer,
using the theoretically calculated molar extinction coefficient
(32,200 M1 cm1 for GOB-18, Gln1163His GOB-18 or
Asp1203 Ser GOB-18, and 32,075 M1 cm1 for Cys2013 Ser
GOB-18) (38).
Biochemical Characterization of Wild-type GOB-18 and
Mutants—Size exclusion chromatography was done on a
Superdex 200 HR 10/30 column (Amersham Biosciences). The
molecular mass of purified GOB-18 was measured by mass
spectrometry/electrospray using an LCQ Duo Ion Trap mass
spectrometer at the mass spectrometry facility LANAIS-PRO,
University of Buenos Aires.
Circular Dichroism spectra of protein samples in 10 mM
Tris-HCl, pH 7.5, and 50 mM NaCl were measured at 25 °C,
using a Jasco J-715 spectropolarimeter flushed with N2.
The amount of solvent exposed cysteine thiols in GOB-18
was determined employing 5,5-dithiobis-(2-nitrobenzoic
acid) in native and SDS-unfolded samples (39).
The GOB-18 and Gln1163His GOB-18 apoproteins were
prepared by treating samples0.1 mM in 10 mM Tris-HCl, pH
7.0, with chelating agents in mild denaturing conditions (see
supplemental material). The Zn(II) derivatives were prepared
by dialyzing the apo-GOB-18 or apo-Gln1163His GOB-18
against 100 volumes of 10 mM Tris-HCl, pH 7.0, 50 mM NaCl,
with an equimolar concentration ofZnSO4.The Fe(II)-GOB-18
derivative was prepared in the same way using instead
(NH4)Fe(SO4), under anaerobic conditions, with O2-free N2
FIGURE 1.Metallo--lactamasemetal binding sites: B. cereus BcII (B1, Protein Data Bank code 1bc2, left)
(14),A.hydrophilaCphA(B2,ProteinDataBankcode1x8g, center) (25), andS.maltophiliaL1 (B3,Protein
Data Bank code 1sml, right) (28). Zinc atoms are shown as gray spheres, and water molecules (W) are shown
as small gray spheres. Coordination bonds are shown as dashed lines.
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efflux and addition of 1 mM sodium dithionite. The reduced
state of the metal ion was verified colorimetrically using o-phe-
nanthroline. The Fe(III)-GOB-18 derivative was prepared tak-
ing advantage of Zn(II) dissociation at acidic pH values retain-
ing the iron content. Holo-GOB-18 was dialyzed against 100
volumes of polybuffer TAMS (50 mM Tris, 50 mM sodium ace-
tate, 50mMMES, and 500mMNaCl) adjusted to pH 4.5 (twice).
Then pH was raised by dialysis against 100 volumes of 10 mM
Tris-HCl, pH 7, and 50 mM NaCl (twice).
Metal Content Determination—The metal content of the
purified enzymeswasmeasured by inductively coupled plasma-
atomic emission spectrometer or by atomic absorption spec-
troscopy in a Metrolab 250 instrument operating in the flame
mode.
Determination of IC50Value—The concentration required to
effect 50% inhibition of enzyme activity (IC50) was determined
by preincubating GOB-18 (2 nM) in 15 mM Hepes, pH 7.5, 200
mM NaCl, 30 °C, with increasing EDTA concentrations for 1
min, prior to the initiation of the assay by the addition of 1 mM
cefotaxime. A plot of steady-state hydrolysis rate versus inhib-
itor concentration provided the basis for the assessment of the
IC50 value.
Determination of the Kinetic Parameters—The hydrolysis of
the antibiotics was monitored by following the absorbance var-
iation resulting from the hydrolysis of the -lactam ring. The
reaction medium employed was 15 mM Hepes, pH 7.5, 0.2 M
NaCl. All measurements were performed at 30 °C. The kinetic
parameters Km and kcat were derived from initial rate measure-
ments, recorded on a JascoV-550 spectrophotometer, andwere
estimated by nonlinear data fitting to the integrated form of the
Michaelis-Menten equation.
pH Dependence—The pH dependence of GOB-18-mediated
cefotaxime hydrolysis was determined by performingmeasure-
ments in the polybuffer TAMS adjusted from pH 4.0 to pH 8.0
with increments of 0.5 pH units, at 1 mM substrate concentra-
tion (see supplemental material).
X-ray Absorption Spectroscopy—Samples of GOB-18 (1
mM) were prepared with 20% (v/v) glycerol, and loaded in
Lucite cuvettes with 6-m polypropylene windows, before
rapid freezing in liquid nitrogen. X-ray absorption spectra were
measured at the National Synchrotron Light Source
(Brookhaven National Laboratory, Upton, NY), beamline X9B,
with a Si(111) double crystal monochromator; harmonic rejec-
tionwas accomplished using a nickel focusingmirror. Data col-
lection and reduction were accomplished according to pub-
lished procedures (40). XAS data were collected on two
independently isolated samples. As each data set gave similar
results, the spectra were averaged; the data in Fig. 3 represent
the average of the two data sets (12 scans total).
Fourier filteredEXAFSdata (k 1–13Å1;r 0.5–2.1Å,
first shell or 0.1–4.5 Å for multiple scattering fits) were fit uti-
lizing theoretical amplitude and phase functions calculated
with FEFF v.8.00 (41). The zinc-nitrogen scale factor and the
threshold energy, E0, were calibrated to the experimental
spectrum for tetrakis-1-methylimidazole zinc(II) perchlorate,
Zn(MeIm)4 (42), and held fixed (at 0.78 and 21 eV, respec-
tively), as were similarly determined values for iron (0.78 and
21 eV), in all subsequent fits to the data for GOB-18. First
shell fits were then obtained for all reasonable coordination
numbers, including mixed nitrogen/oxygen ligation, while
allowing the absorber-scatterer distance, Ras, and the Debye-
Waller factor, as2, to vary; the best fits are presented in the
supporting information. Multiple scattering contributions
from histidine ligands were fit according to published proce-
dures. Metal-metal (zinc-iron and iron-zinc) scattering was
modeled with reference to the experimental EXAFS of
Zn2(salpn)2 and Fe2(salpn)2.
NMR—NMR spectra were recorded on a Bruker Avance II
600 spectrometer operating at 600.13MHz at different temper-
atures, as indicated. 1HNMR spectra were recorded under con-
ditions to optimize detection of the fast relaxing paramagnetic
resonances, either using the superWEFT pulse sequence or
water presaturation. Spectra were acquired over large spectral
widths with acquisition times ranging from 16 to 80 ms and
intermediate delays from 2 to 35 ms. One-dimensional experi-
ments with solvent presaturation were used to record isotropi-
cally shifted signals closer to the diamagnetic envelope.
EPR—EPRwas recorded at 9.63 GHzwith 2-milliwatt micro-
wave power and 5-G (0.5mT)magnetic fieldmodulation at 100
kHz, using a Bruker EleXsys E500 spectrometer equipped with
an ER4116DM cavity operating in perpendicular mode and an
Oxford Instruments ESR900 helium flow cryostat and ITC503
temperature controller.
RESULTS
Biochemical Characterization of GOB-18—The gene coding
for a GOB-type ML was cloned from a carpabenem-resistant
E. meningoseptica clinical strain. Sequence analysis indicated a
predicted molecular mass of 31.4 kDa for the encoded protein.
At the time of sequencing therewere 17 known variants ofGOB
enzymes. This protein differed from those reported previously
and was named GOB-18. This enzyme differed from the firstly
reported GOB enzyme, GOB-1 (32), by three conserved muta-
tions: Leu943 Phe, Ala1373 Val, andAsp2823 Asn (standard
consensus numbering) (5).
Recombinant GOB-18 was overproduced as a fusion to GST
in the cytoplasm of E. coli BL21(DE3) pLysS cells, cleaved, and
purified tohomogeneity.GOB-18 is amonomeric enzymeaccord-
ing to size exclusion chromatography. Mass spectrometry con-
firmed themolecularmass expected from the gene sequence. The
-lactamase activity (measured as cefotaxime hydrolysis) was
inhibited by EDTAwith an IC50 of 2.3 0.3mM, indicating that
GOB-18 holds a tightly bound divalent cation essential for
activity. Inductively coupled plasma and atomic absorption
analyses showed that recombinant GOB-18 contained signifi-
cant amounts of zinc and, notably, iron. Although the relative
amounts of these two metals varied among different enzyme
preparations (0.45–0.75 iron/GOB-18 and 0.01–0.20 zinc/
GOB-18), the total metal content never exceeded onemetal ion
per proteinmolecule. Addition of excess Zn(II) did not alter the
CD spectrum of GOB-18 as isolated, neither in the near nor in
the far UV (data not shown). Overall, these data suggest that
GOB-18 is a mono-metallic enzyme, in sharp contrast to the
other B3 MLs.
The apoprotein was devoid of lactamase activity that could
be recovered by addition of Zn(II). Remarkably, apo-GOB-18
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remetallated with Zn(II) bound only one equivalent of Zn(II)
and its activity largely exceeded that of the enzyme as isolated
(Fig. 2). On the other hand, Fe(II)-GOB-18 and Fe(III)-GOB-18
displayed negligible activities compared with that of Zn(II)-
GOB-18. In fact, Fe(III)-GOB-18 was poorly active even upon
addition of Zn(II), suggesting that both metal ions compete for
the same binding site. The kinetic parameters of Zn(II)-GOB-
18, reported in Table 1, show that mono-Zn(II)-GOB-18 pre-
sents a broad substrate spectrum for-lactams, similarly to that
shown by dinuclear B3 enzymes. Addition of 20 M Zn(II) to
the reaction medium did not modify the enzyme kinetic
parameters.
The pH dependence of GOB-18-mediated cefotaxime
hydrolysis showed a plateau between pH values of 6 and 8, and
an acidic limb, resulting in a complete inactivation at pH 4.5.
This loss of activity could be reverted by raising the pH to 6.5,
indicating that the inactivation is reversible. Metal content
analysis at different pH values showed that the decrease in
activity at low pH paralleled the dissociation of Zn(II) from the
enzyme, despite the fact that most of the Fe(III) remained
bound up to pH 4 (see supplemental material).
Overall, these data show that Zn(II)-GOB-18 is the active
-lactamase species. GOB-18 preparations with larger zinc/
iron ratios were the most active ones, in line with this observa-
tion (see supplemental material). Expression of the complete
GOB-18 gene (including a transit peptide sequence) in E. coli
results in an enzyme secreted to the periplasm confering -lac-
tam resistance to the bacterial host. Isoelectrofocusing analysis
of the periplasmic fraction after osmotic shock revealed that the
enzyme is present exclusively in the Zn(II) form, suggesting
that iron uptake could be due to an artifact of protein overex-
pression in E. coli cytoplasm.
X-ray Absorption Spectroscopy—EXAFS data recorded at the
zinc and iron edges, k3((k), and the corresponding Fourier
transforms for GOB-18 are shown in Fig. 3. EXAFS curve-fit-
ting results are presented as supporting information. Fits to
Fourier-filtered first shell scattering (0.5–2.1 Å) in the case of
Zn(II)-GOB-18 suggest coordination to 4 nitrogen/oxygen
donors at a distance of 2.01 Å (Fit Zn-1). Fit residuals did not
improve significantly upon inclusion of a sulfur, or amixed shell
of nitrogen/oxygen. Multiple scattering analysis indicates liga-
tion to 2 histidine residues (Fit Zn-2). The low Debye-Waller
factor for the second multiple scattering path (C1-N1) most
likely reflects some rotation of the imidazole plane about the
axis normal to the zinc-nitrogen bond. Inclusion of a single
zinc-carbon scattering interaction at a distance of 2.71 Å, rep-
resenting carboxylate carbon scattering, modestly improved
the fit (15%) (Fit Zn-3).
In the case of Fe(III)-GOB-18, single shell fits give an average
of 5 nitrogen/oxygen scatterers at 2.11 Å (Fit Fe-1). Inclusion of
a sulfur atom increased the fit residual. The larger metal-ligand
distance is consistent with a higher coordination number for
iron relative to zinc. Separate shells of 3 oxygen atoms at 2.04 Å
and 2 nitrogen atoms at 2.20 Å could be resolved (Fit Fe-2), and
multiple scattering fits indicate the presence of two His ligands
(Fit Fe-3). Inclusion of an iron scatterer in fits for Zn(II)-
GOB-18 (Fit Zn-4) and a zinc scatterer in fits for Fe(III)-
GOB-18 (Fit Fe-3) slightly improved the fits but led to different
metal-metal distances (3.61 and 3.55 Å, respectively). This
allows us to discard the existence of a heterodimetallic site in
GOB-18. Thus, EXAFS data, together with the biochemical
studies, suggest that Zn(II) and Fe(III) compete for the only
metal binding site in GOB-18. Based on this, we decided to
exploit Fe(III) as a spectroscopic probe of the metal site.
Spectroscopic Characterization of Fe(III)-GOB-18—The UV-
visible spectrum of Fe(III)-GOB-18 revealed an absorption
band centered at 375 nm, which was not present in the apoen-
zyme nor in the Zn(II)-reconstituted form (Fig. 4A). This fea-
ture can be attributed to a typical His-Fe(III) charge transfer
band, similar to those observed in lipoxygenase, iron superox-
ide dismutase, and other non-heme, non-Fe-S iron proteins
(43). EPR spectra of GOB-18 recorded at 6 K and 25 K (Fig. 4B)
indicated an isolated, “rhombic” (i.e. mean E/D  1/3) Fe(III)
FIGURE 2. Activity of the different GOB-18metal derivatives determined
against 1mM cefotaxime. Specific activity was defined as the rate of hydrol-
ysis (M s1) per unit enzyme concentration (M). Samples are: GOB-18 as
isolated (Holo), apo-GOB-18 (Apo), Zn(II)-remetallated apo-GOB-18 (Zn(II)),
Fe(III)-GOB-18 (Fe(III)), Fe(II)-GOB-18 (Fe(II)). GOB-18 metal derivatives were
prepared as described under “Experimental Procedures.” Metal content of
each sample is detailed at the bottom. --, less than 0.001.
TABLE 1
Kinetic parameters for the hydrolysis of different -lactam substrates by fully loaded wild type Zn(II)-GOB-18 and Zn(II)-Gln1163 His GOB-18
mutant
Kinetic parameters derived from a nonlinear fit of Michaelis-Menten equation to initial rate measurements. Reported values are the average of at least three independent
enzyme preparations. ND, not determined.
Substrate GOB-18 Gln
1163 His GOB-18
kcat Km kcat/Km kcat Km kcat/Km
s1 M M1 s1 s1 M M1 s1
Penicillin G 680 80 330 30 2.1 0.4 664 9 380 20 1.7 0.1
Cefaloridine 30 2 31.5 0.5 0.95 0.08 ND ND
Cefotaxime 83 2 88 6 0.94 0.09 13.1 0.1 58 2 0.23 0.01
Imipenem 42 9 26 2 1.6 0.5 19.3 0.4 58 3 0.33 0.02
Meropenem 72.5 0.5 40 10 1.8 0.5 ND ND
Metallo--lactamase GOB Is aMono-Zn(II) Enzyme
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ion. The almost complete loss of the MS  1/2 (or MS 
5/2) signals at 25 K suggests a zero field splitting, , of less
than about 30 cm1. The asymmetry of the lines at geff 4.3
and at geff 9 indicates significant strain in E/D, although the
shoulder on the crossover at geff 4.3 (Fig. 4B, inset) indicates a
lower degree of strain than in the often-seen “adventitious iron”
signal and provides strong evidence for the Fe(III) being tightly
protein-bound. In contrast to the iron-loaded glyoxylase II (44),
no signals attributable to an Fe(III)-Fe(II) coupled system were
observed from GOB-18.
1H NMR spectra recorded under conditions that allow the
detection of paramagnetic signals revealed a set of isotropically
shifted resonances spanning from 100 to 20 ppm (Fig. 4C): a
broad feature (A), accounting for three resonances centered at
80 ppm, a signal of fractional intensity at 38 ppm (B), and a
two-proton resonance at 30 ppm (C). When the spectrum was
recorded in D2O, a loss of intensity corresponding to two pro-
tons was noticed in the broad envelope A, revealing the pres-
ence of two exchangeable resonances. The broad nature of
these resonances is comparable with that reported for mono-
nuclear Fe(III) enzymes such as protocatechuate dioxygenase
(45), allowing us to discard the presence of a coupled, di-iron
site. The two exchangeable resonances located at80 ppm can
be attributed to two His ligands, in agreement with the analysis
of the EXAFS data. The broad nature of these signals prevented
us to perform one-dimensional or two-dimensional nuclear
Overhauser effect spectra to assign them.
Altogether, EPR, NMR, and EXAFS data allow us to rule out
the formation of a dinuclear Fe(III) site in GOB-18, supporting
the above assumption that Fe(III) and Zn(II) bind to the same
site. EXAFS and NMR reveal the presence of two His ligands at
themetal site, with five nitrogen/oxygen ligands for Fe(III). The
1H NMR spectrum shows only 5–6 resonances corresponding
to metal ligands, two of them corresponding to imidazolic His
NHs, suggesting that one or two water molecules would be
needed to achieve a penta-coordinated site.
This picture can be accounted for by two possibilities: (i) that
the metal ion binds to a modified Site 1 in GOB-18, in which
His116 has been replaced by a Gln residue, with His118, His196,
and aH2O/OHmoiety completing the coordination sphere or
(ii) by placing the metal ion into Site 2 (DHH ligand set), with
Asp120, His121, His263, and a H2O/OH as metal ligands.
Three-dimensional Modeling—Three-dimensional models
for Zn(II)-GOB-18 were built by homology modeling from the
two available x-ray structures of B3 MLs: FEZ-1 and L1 (38
and 21% sequence identity, respectively), including metal-li-
gand constraints based on spectroscopic data. We examined
the possibility of binding a single Zn(II) ion to each of the two
canonical metal binding sites. Best GOB-18 models for both
mono-zinc active site conformations show low backbone root
mean square deviation compared with FEZ-1 and L1 (0.6 and
1.5 Å, respectively), suggesting that the protein fold can accom-
modate a single Zn(II) ion in either binding site. Quantum
chemical geometry optimizations based on density functional
theory on unconstrainedmodels of thesemetal sites with water
or hydroxide as the fourth ligand suggested a regular tetrahe-
dral geometry for a Zn(II) ion at a modified Site 1 and a dis-
torted tetrahedron for the metal ion bound to Site 2. Predicted
averaged zinc-nitrogen/oxygen distances are within 0.04 Å
from the values retrieved fromEXAFS data, preventing us from
discerning between the two sites (see supplementalmaterial for
additional “Experimental Procedures”).
Site-directed Mutagenesis of Putative Metal Ligands—To
unequivocally identify the metal binding site in GOB-18, we
constructed mutants of possible metal ligands. In one of them
FIGURE 3. Fourier transformed EXAFS data of mono-zinc (top, solid lines)
andmono-iron (bottom, solid lines) GOB-18, and corresponding best fits
(open diamonds). The fits correspond to fits Zn-2 and Fe-3 in Table S1.
FIGURE 4. Spectroscopic data on GOB-18. A, UV-visible spectra of GOB-18 as isolated (black line) and apo-enzyme (gray line). The inset shows the His-Fe(III)
charge transfer band at 375 nm. The corresponding spectrum of Zn(II)-GOB-18 is indistinguishable from that of apo-GOB-18 in the wavelength range shown.
B, X-bandEPR spectra of 300MGOB-18 inbuffer 15mMHepes, pH7.5, 0.2 MNaClwith 25%glycerol, at 6 K (top) and25 K (bottom); the inset shows anexpanded
region of the spectrum recorded at 6 K. C, NMR spectra of GOB-18 and Gln1163 His GOB-18 in buffer 15 mM Hepes, pH 7.5, 0.2 M NaCl with 10% D2O. The
enzymes were 1.1 mM. The intensity of signals indicated with * decrease in D2O. Black line, GOB-18; gray line, Gln
1163 His GOB-18.
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Asp120, which is conserved in all MLs as a Zn2 ligand, was
changed to Ser; and Gln116, distinctive of GOB enzymes, was
replaced by a His. The Gln1163His mutant, in particular,
would be expected to provide a 3-H binding site similar to that
found in all B1 and in most B3 MLs (12, 15, 28, 31).
Gln1163His GOB-18 was purified as a mixture of zinc and
iron forms, typically with 0.06–0.70 zinc/protein and 0.20–
0.60 iron/protein. Remarkably, the total metal content of this
mutant never exceeded one equivalent per protein, as deter-
mined for wild-type GOB-18. Apo-Gln1163His GOB-18
remetallated with Zn(II) bound only one equivalent of Zn(II).
The kinetic parameters of zinc-Gln1163His GOB-18 showed
a partially decreased activity when compared with that of wild-
typeGOB-18 (Table 1). Addition of 20MZn(II) to the reaction
medium gave rise to minor changes in the mutant enzyme
activity (data not shown). UV-visible and EXAFS data at the
iron edge of holo-Gln1163HisGOB-18were identical to those
recorded for the wild-type enzyme. Similarly, the paramagnetic
1HNMR spectrum of this mutant showedminor perturbations
in the Fe(III) ligand signals when compared with that of the
wild-type enzyme (Fig. 4C). The fact that themetal site is largely
unperturbed suggests that residue 116 is not a metal ligand
neither in wild-type GOB-18 nor in Gln1163His GOB-18.
Asp1203 SerGOB-18 displayed amarkedly decreasedmetal
binding ability for both iron and zinc. The iron binding capacity
of Asp1203 Ser GOB-18 was abolished, and the Zn(II) content
reached at most 0.45 Zn(II)/protein (even after exhaustive dial-
ysis against metal containing buffer). Asp1203 Ser GOB-18
was inactive toward different assayed antibiotics. These data
reveal that Asp120 is a metal ligand, being also essential for cat-
alytic efficiency.
B1 and B2 MLs have a Cys ligand in the Zn2 site (15, 25).
The present three-dimensional model suggests that the only
Cys residue present in GOB-18 is far away from the active site.
This Cys residue is only accessible to 5,5-dithiobis-(2-nitro-
benzoic acid) under denaturing conditions. To definitively dis-
card the possibility that this Cys residue may serve as a metal
ligand in GOB-18, we constructed a Cys2013 Ser mutant. The
metal content, catalytic efficiency, and spectroscopic data of
Cys2013 Ser GOB-18 were similar to those of the wild-type
enzyme, indicating the absence of a Cys ligand in the metal
binding site, in agreement with the present three-dimensional
model and EXAFS data.
DISCUSSION
GOB Enzymes Are Monometallic Lactamases—The bio-
chemical, spectroscopic, and mutagenesis data herein shown
allow us to propose that GOB-18 is amono-metallicML, with
the catalytic Zn(II) ion bound to Asp120, His121, His263, i.e. the
canonical Zn2 site (DHH ligand set in subclass B3) (Fig. 5). The
coordination sphere would be completed by one or two solvent
molecules in the Zn(II) and Fe(III) variants, respectively. The
presence of a naturally occurring Gln residue rather than a His
at position 116 in GOB-18 resembles the situation found for
subclass-B2 MLs, in which an Asn is found (25, 27). In both
cases, the absence of the otherwise conserved His116 ligand
would induce the loss of the Zn1 site. However, engineering a
putative 3-H site in GOB-18 does not lead to a dimetallic
enzyme, suggesting additional structural differences in the
metal site of GOB-18.
GOB enzymes differ by a few point mutations, apparently far
from the active site. This allows us to confidently extend our
results to all GOB lactamases. GOBMLs thus present features
of B2 (being Zn2-only enzymes) and B3 (based on sequence
homology) lactamases.However, twomajor differences ofGOB
MLs with B2 enzymes should be noted: (i) GOB is active even
in the presence of 0.1 mM Zn(II), while B2 enzymes are inhib-
ited upon binding of a second Zn(II) equivalent and; (ii) B2
enzymes are selective carbapenemases, while GOB is a broad
spectrumML. Thus, GOBMLs are unique in being the only
broad spectrum mono-Zn(II) -lactam hydrolases and in pre-
senting active site mutations within one subclass.
Toward a General Catalytic Mechanism for Metallo--
Lactamases—The effect of the Zn(II) content on the enzymatic
activity inMLs is still a controversial issue. The Zn1 (3-H) site
present in all B1 and inmost B3 enzymes, GOBMLs being the
only exception, has been regarded as the catalytic site providing
the attacking zinc-bound nucleophile. As inferred from a series
of elegant spectroscopic studies, the Zn2 site (DCH ligand set in
B1 enzymes and DHH ligands in B3 lactamases) contributes to
-lactam hydrolysis by binding to the bridging -lactam nitro-
gen (17, 18, 46). The trapping of hydrolyzed moxalactam in the
active site of S. maltophilia L1 recently confirmed that both
Zn1 andZn2 are implicated in substrate binding and catalysis in
B3 MLs (47).
The structure of both the free and product-complexed
form of the B2 enzyme CphA revealed only one catalytic
Zn(II) ion bound to the DCH site (25). This metal ion is also
involved in stabilization of the negative charge on the bridg-
ing nitrogen atom of the -lactam ring, as in B1 and B3
enzymes. Thus, the Zn2 site would play the same role in all
MLs, i.e. the stabilization of the negative charge developed
at the -lactam nitrogen to favor cleavage of the C–N bond,
and the proton delivery through a water molecule bound to
it. This is further stressed by the fact that in all studied cases,
the rate-determining step is the C–N bond cleavage (that
FIGURE 5. Molecular model of the zinc binding site of GOB-18. The zinc
atom (Zn) is shownas agray sphere, and thewatermolecules (W) are shownas
small gray spheres. Coordination bonds are shown as dashed lines.
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involves the Zn2 ion) (16, 17, 46, 48). This suggests that a
strategy aimed for the design of a general inhibitor could be
pursued by targeting the Zn2 site.
The issue that remains unsolved is the identification of the
nucleophile in Zn2-only enzymes. The absence of the Zn1
site in B2 lactamases has led to the proposal of a non-metal
activated nucleophile, a hypothesis later supported by theo-
retical and enzymological studies (48, 49). However, the pos-
sibility of a Zn2-bound nucleophile cannot been definitively
ruled out. The results herein presented reveal that Zn2-only
MLs are not only restricted to B2 subclass and that they can
display a broad substrate spectrum. Therefore, a general
mechanism of Zn2-only enzymes needs to be definitively
elucidated and compared with those of dinuclear and Zn1-
only enzymes.
Several reports have indicated that the mono-Zn(II) variants
of B1 and B3 enzymes are active (50, 51). Since the first solved
ML structure revealed one metal ion bound to the 3-H site
(12), this has been regarded as the catalytic center in monome-
tallic variants. However, spectroscopic data have revealed that
when BcII (a well studied B1 lactamases) binds one equivalent
of metal ion, it is distributed between the canonical Zn1 and
Zn2 sites (52, 53). These data should be reanalyzed at the light
of the present evidence, considering that active mono-Zn2
enzymes may also occur among B1 and B3 enzymes other than
GOB.
Acknowledgment—We thank Dr. R. Girolami for atomic absorption
measurements.
REFERENCES
1. Fisher, J. F., Meroueh, S. O., and Mobashery, S. (2005) Chem. Rev. 105,
395–424
2. Wilke, M. S., Lovering, A. L., and Strynadka, N. C. (2005) Curr. Opin.
Microbiol. 8, 525–533
3. Frere, J. M., Galleni, M., Bush, K., and Dideberg, O. (2005) J. Antimicrob.
Chemother. 55, 1051–1053
4. Hall, B. G., Salipante, S. J., and Barlow, M. (2003) J. Mol. Evol. 57,
249–254
5. Galleni, M., Lamotte-Brasseur, J., Rossolini, G. M., Spencer, J., Dide-
berg, O., and Frere, J. M. (2001) Antimicrob. Agents Chemother. 45,
660–663
6. Garau, G., Di Guilmi, A. M., and Hall, B. G. (2005) Antimicrob. Agents
Chemother. 49, 2778–2784
7. Walsh, T. R., Toleman, M. A., Poirel, L., and Nordmann, P. (2005) Clin.
Microbiol. Rev. 18, 306–325
8. Wang, Z., Fast,W., Valentine, A.M., and Benkovic, S. J. (1999)Curr. Opin.
Chem. Biol. 3, 614–622
9. Cricco, J. A., Rasia, R. M., Orellano, E. G., Ceccarelli, E. A., and Vila, A. J.
(1999) Coord. Chem. Rev. 190–192, 519–535
10. Cricco, J. A., and Vila, A. J. (1999) Curr. Pharm. Des 5, 915–927
11. Crowder, M. W., Spencer, J., and Vila, A. J. (2006) Acc. Chem. Res. 39,
721–728
12. Carfi, A., Pares, S., Duee, E., Galleni, M., Duez, C., Fre`re, J. M., and Dide-
berg, O. (1995) EMBO J. 14, 4914–4921
13. Orellano, E. G., Girardini, J. E., Cricco, J. A., Ceccarelli, E. A., and Vila, A. J.
(1998) Biochemistry 37, 10173–10180
14. Fabiane, S. M., Sohi, M. K., Wan, T., Payne, D. J., Bateson, J. H., Mitchell,
T., and Sutton, B. J. (1998) Biochemistry 37, 12404–12411
15. Concha, N., Rasmussen, B. A., Bush, K., andHerzberg, O. (1996) Structure
(Camb.) 4, 823–836
16. Yanchak,M. P., Taylor, R. A., andCrowder,M.W. (2000)Biochemistry 39,
11330–11339
17. Wang, Z., Fast, W., and Benkovic, S. J. (1999) Biochemistry 38,
10013–10023
18. Wang, Z., Fast, W., and Benkovic, S. J. (1998) J. Am. Chem. Soc. 120,
10788–10789
19. Garcia-Saez, I., Hopkins, J., Papamicael, C., Franceschini, N., Amicosante,
G., Rossolini, G. M., Galleni, M., Frere, J. M., and Dideberg, O. (2003)
J. Biol. Chem. 278, 23868–23873
20. Docquier, J. D., Lamotte-Brasseur, J., Galleni, M., Amicosante, G., Frere,
J. M., and Rossolini, G. M. (2003) J. Antimicrob. Chemother. 51, 257–266
21. Materon, I. C., Beharry, Z., Huang, W., Perez, C., and Palzkill, T. (2004) J.
Mol. Biol. 344, 653–663
22. Toney, J. H., Hammond, G. G., Fitzgerald, P. M., Sharma, N., Balkovec,
J. M., Rouen, G. P., Olson, S. H., Hammond, M. L., Greenlee, M. L., and
Gao, Y. D. (2001) J. Biol. Chem. 276, 31913–31918
23. Toleman, M. A., Simm, A. M., Murphy, T. A., Gales, A. C., Biedenbach,
D. J., Jones, R. N., and Walsh, T. R. (2002) J. Antimicrob. Chemother. 50,
673–679
24. Murphy, T. A., Catto, L. E., Halford, S. E., Hadfield, A. T., Minor, W.,
Walsh, T. R., and Spencer, J. (2006) J. Mol. Biol. 357, 890–903
25. Garau,G., Bebrone, C., Anne, C., Galleni,M., Frere, J.M., andDideberg,O.
(2005) J. Mol. Biol. 345, 785–795
26. Herna´ndez Valladares, M., Felici, A., Weber, G., Adolph, H.W., Zeppeza-
uer, M., Rossolini, G. M., Amicosante, G., Fre`re, J. M., and Galleni, M.
(1997) Biochemistry 36, 11534–11541
27. Crawford, P. A., Yang, K.W., Sharma,N., Bennett, B., andCrowder,M.W.
(2005) Biochemistry 44, 5168–5176
28. Ullah, J. H.,Walsh, T. R., Taylor, I. A., Emery, D. C., Verma, C. S., Gamblin,
S. J., and Spencer, J. (1998) J. Mol. Biol. 284, 125–136
29. Spencer, J., Clarke, A. R., and Walsh, T. R. (2001) J. Biol. Chem. 276,
33638–33644
30. Garrity, J. D., Carenbauer, A. L., Herron, L. R., and Crowder,M.W. (2004)
J. Biol. Chem. 279, 920–927
31. Garcia-Saez, I., Mercuri, P. S., Papamicael, C., Kahn, R., Frere, J. M., Gal-
leni, M., Rossolini, G. M., and Dideberg, O. (2003) J. Mol. Biol. 325,
651–660
32. Bellais, S., Aubert, D., Naas, T., and Nordmann, P. (2000) Antimicrob.
Agents Chemother. 44, 1878–1886
33. Docquier, J. D., Pantanella, F., Giuliani, F., Thaller, M. C., Amicosante, G.,
Galleni, M., Frere, J. M., Bush, K., and Rossolini, G. M. (2002) Antimicrob.
Agents Chemother. 46, 1823–1830
34. Docquier, J. D., Lopizzo, T., Liberatori, S., Prenna, M., Thaller, M. C.,
Frere, J. M., and Rossolini, G. M. (2004) Antimicrob. Agents Chemother.
48, 4778–4783
35. Ausubel, K. M., Brent, R., Kingston, R. E., Moore, R. E., Seidman, I. G.,
Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology,
John Wiley & Sons, New York
36. Costa, G. L., Bauer, J. C., McGowan, B., Angert, M., and Weiner, M. P.
(1996) in In Vitro Mutagenesis Protocols (Trower, M. K., ed) Humana
Press, Totowa, NJ
37. Laemmli, U. K. (1970) Nature 227, 680–685
38. Gill, S. C., and von Hippel, P. H. (1989) Anal. Biochem. 182, 319–326
39. Riener, C. K., Kada, G., andGruber, H. J. (2002)Anal. Bioanal. Chem. 373,
266–276
40. Thomas, P. W., Stone, E. M., Costello, A. L., Tierney, D. L., and Fast, W.
(2005) Biochemistry 44, 7559–7569
41. Ankudinov, A. L., Ravel, B., Rehr, J. J., and Conradson, S. D. (1998) Phys.
Rev. B 58, 7565–7576
42. McClure, C. P., Rusche, K.M., Peariso, K., Jackman, J. E., Fierke, C. A., and
Penner-Hahn, J. E. (2003) J. Inorg. Biochem. 94, 78–85
43. Averill, B. A., and Vincent, J. B. (1993)Methods Enzymol. 226, 33–51
44. Marasinghe, G. P., Sander, I. M., Bennett, B., Periyannan, G., Yang, K. W.,
Makaroff, C. A., and Crowder, M. W. (2005) J. Biol. Chem. 280,
40668–40675
45. Que, L., Jr., Lauffer, R. B., Lynch, J. B., Murch, B. P., and Pyrz, J. W. (1987)
J. Am. Chem. Soc. 109, 5381–5385
46. McManus-Mun˜oz, S., and Crowder, M. W. (1999) Biochemistry 38,
1547–1553
Metallo--lactamase GOB Is aMono-Zn(II) Enzyme
18292 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 25•JUNE 22, 2007
 at M
A
RQUETTE UNIV on April 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
47. Spencer, J., Read, J., Sessions, R. B., Howell, S., Blackburn, G. M., and
Gamblin, S. J. (2005) J. Am. Chem. Soc. 127, 14439–14444
48. Sharma, N. P., Hajdin, C., Chandrasekar, S., Bennett, B., Yang, K. W., and
Crowder, M. W. (2006) Biochemistry 45, 10729–10738
49. Xu, D., Xie, D., and Guo, H. (2006) J. Biol. Chem. 281, 8740–8747
50. Wommer, S., Rival, S., Heinz, U., Galleni,M., Frere, J.M., Franceschini, N.,
Amicosante, G., Rasmussen, B., Bauer, R., andAdolph,H.W. (2002) J. Biol.
Chem. 277, 24142–24147
51. Costello, A., Periyannan, G., Yang, K. W., Crowder, M. W., and Tierney,
D. L. (2006) J. Biol. Inorg. Chem. 11, 351–358
52. de Seny, D., Heinz, U., Wommer, S., Kiefer, M., Meyer-Klaucke, W., Gal-
leni, M., Frere, J. M., Bauer, R., and Adolph, H. W. (2001) J. Biol. Chem.
276, 45065–45078
53. Hemmingsen, L., Damblon, C., Antony, J., Jensen, M., Adolph, H. W.,
Wommer, S., Roberts, G. C., and Bauer, R. (2001) J. Am. Chem. Soc. 123,
10329–10335
Metallo--lactamase GOB Is aMono-Zn(II) Enzyme
JUNE 22, 2007•VOLUME 282•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 18293
 at M
A
RQUETTE UNIV on April 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Limansky, Alejandro M. Viale and Alejandro J. Vila
Matteo Dal Peraro, Paolo Carloni, Brian Bennett, David L. Tierney, Adriana S. 
Jorgelina Morán-Barrio, Javier M. González, María Natalia Lisa, Alison L. Costello,
-lactamase GOB Is a Mono-Zn(II) Enzyme with a Novel Active SiteβThe Metallo-
doi: 10.1074/jbc.M700467200 originally published online April 2, 2007
2007, 282:18286-18293.J. Biol. Chem. 
  
 10.1074/jbc.M700467200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2007/04/03/M700467200.DC1
  
 http://www.jbc.org/content/282/25/18286.full.html#ref-list-1
This article cites 51 references, 17 of which can be accessed free at
 at M
A
RQUETTE UNIV on April 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
